Auria
Breast Cancer Screening
CommercialActive
Key Facts
About Namida Lab
Namida Lab is a revenue-stage diagnostics company pioneering the use of tears as a biofluid for early cancer detection. Its core technology platform analyzes the proteomic and genomic content of tears to identify biomarkers associated with cancers, starting with breast cancer. The company has commercialized two initial products: Auria, an at-home breast cancer screening test, and Melody, a clinical diagnostic for providers. By focusing on a non-invasive, easily collectible fluid, Namida Lab aims to disrupt traditional screening paradigms and improve patient compliance and outcomes.
View full company profileTherapeutic Areas
Other Breast Cancer Screening Drugs
| Drug | Company | Phase |
|---|---|---|
| Non-Contrast Breast MRI Screening Research | Ikonopedia | Research |
| Electrical Mammogram | NovaScan | Pre-clinical |
| Thermalytix | Niramai | Approved |
| KBCT for Primary Screening | Koning | Research / Aspirational |
| Breast Cancer Screening AI | Vara | Commercial |
| PRISM Randomized Controlled Trial | ScreenPoint Medical | Trial |